FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Additional indication for pediatric patients with severe eosinophilic asthma

...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Japan ,Liz Bodin ,Lynda Mitchell ,Minerva Pediatr ,Biowa Inc ,Astrazeneca ,Allergy Asthma Network ,Drug Administration ,World Health Organization ,Kyowa Kirin Co Ltd ,Asthma Network ,Vice President ,Asthma Symptoms ,Prescribing Information ,Patient Information ,Rare Diseases ,Pediatri Allergy Immunol ,Allergy Clin ,Zeneca Annual Report ,Very Severe Chronic Obstructive Pulmonary Disease ,Frequent Exacerbations ,Safety Study ,Patients With Hypereosinophilic Syndrome ,